503832-26-6

Basic information

• Product Name: 1-Naphthalenol, 6-amino-1,2,3,4-tetrahydro-
• CAS NO: 503832-26-6
• Molecular Formula: C10H13NO
• Molecular Weight: 163.219
• Mol File: 503832-26-6.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 1-Naphthalenol, 6-amino-1,2,3,4-tetrahydro-(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Naphthalenol, 6-amino-1,2,3,4-tetrahydro-(503832-26-6)
• EPA Substance Registry System: 1-Naphthalenol, 6-amino-1,2,3,4-tetrahydro-(503832-26-6)

Safety Data

• Hazardous Substances Data: 503832-26-6(Hazardous Substances Data)

Usage

Aromatic amine

Contains a six-membered ring with nitrogen

Synthesis methods

Can be synthesized through various methods

Appearance

Pale yellow to tan

Uses

Commonly used as intermediate in synthesis of pharmaceuticals and dyes, may have applications in organic synthesis and as a chemical reagent

Safety

Can have harmful effects on human health if not used properly

Upstream product

• 23894-12-4 6-aminonaphthalen-1-ol 
• 3470-53-9 6-amino-1-tetralone 
• 22246-26-0 6-nitrotetralone 

Relevant articles and documents

Selective Catalytic Hydrogenation of Arenols by a Well-Defined Complex of Ruthenium and Phosphorus-Nitrogen PN3-Pincer Ligand Containing a Phenanthroline Backbone

Selective catalytic hydrogenation of aromatic compounds is extremely challenging using transition-metal catalysts. Hydrogenation of arenols to substituted tetrahydronaphthols or cyclohexanols has been reported only with heterogeneous catalysts. Herein, we demonstrate the selective hydrogenation of arenols to the corresponding tetrahydronaphthols or cyclohexanols catalyzed by a phenanthroline-based PN3-ruthenium pincer catalyst.

Compounds for the treatment of pain

This invention provides methods of treating pain, urinary incontinence and other abnormalities mediated by a NPFF receptor, which comprises administering to a subject a therapeutically effective amount of a chemical compound which acts at the NPFF1 receptor, the NPFF2 receptor, or at both the NPFF1 and NPFF2 receptors.